Das Suchergebnis hat sich seit Ihrer Suchanfrage verändert. Eventuell werden Dokumente in anderer Reihenfolge angezeigt.
  • Treffer 6 von 11
Zurück zur Trefferliste

Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma

  • Background: MicroRNA-21 (miR-21) is up-regulated in tumor tissue of patients with malignant diseases, including hepatocellular carcinoma (HCC). Elevated concentrations of miR-21 have also been found in sera or plasma from patients with malignancies, rendering it an interesting candidate as serum/plasma marker for malignancies. Here we correlated serum miR-21 levels with clinical parameters in patients with different stages of chronic hepatitis C virus infection (CHC) and CHC-associated HCC. Methodology/Principal Findings: 62 CHC patients, 29 patients with CHC and HCC and 19 healthy controls were prospectively enrolled. RNA was extracted from the sera and miR-21 as well as miR-16 levels were analyzed by quantitative real-time PCR; miR-21 levels (normalized by miR-16) were correlated with standard liver parameters, histological grading and staging of CHC. The data show that serum levels of miR-21 were elevated in patients with CHC compared to healthy controls (P<0.001); there was no difference between serum miR-21 in patients with CHC and CHC-associated HCC. Serum miR-21 levels correlated with histological activity index (HAI) in the liver (r = −0.494, P = 0.00002), alanine aminotransferase (ALT) (r = −0.309, P = 0.007), aspartate aminotransferase (r = −0.495, P = 0.000007), bilirubin (r = −0.362, P = 0.002), international normalized ratio (r = −0.338, P = 0.034) and γ-glutamyltransferase (r = −0.244, P = 0.034). Multivariate analysis revealed that ALT and miR-21 serum levels were independently associated with HAI. At a cut-off dCT of 1.96, miR-21 discriminated between minimal and mild-severe necroinflammation (AUC = 0.758) with a sensitivity of 53.3% and a specificity of 95.2%. Conclusions/Significance: The serum miR-21 level is a marker for necroinflammatory activity, but does not differ between patients with HCV and HCV-induced HCC.

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar
Metadaten
Verfasserangaben:Verena Bihrer, Oliver WaidmannORCiDGND, Mireen Friedrich-RustORCiDGND, Nicole Forestier, Simone Susser, Jörg HaupenthalORCiDGND, Martin-Walter WelkerGND, Ying Shi, Jan Franz-Josef Peveling-OberhagORCiDGND, Andreas Polta, Michael von Wagner, Heinfried H. RadekeORCiDGND, Christoph SarrazinGND, Jörg TrojanORCiDGND, Stefan ZeuzemORCiDGND, Bernd KronenbergerORCiDGND, Albrecht PiiperORCiD
URN:urn:nbn:de:hebis:30:3-237227
DOI:https://doi.org/doi:10.1371/journal.pone.0026971
ISSN:1932-6203
Pubmed-Id:https://pubmed.ncbi.nlm.nih.gov/22066022
Titel des übergeordneten Werkes (Englisch):PLoS One
Verlag:PLoS
Verlagsort:Lawrence, Kan.
Dokumentart:Wissenschaftlicher Artikel
Sprache:Englisch
Datum der Veröffentlichung (online):31.10.2011
Jahr der Erstveröffentlichung:2011
Veröffentlichende Institution:Universitätsbibliothek Johann Christian Senckenberg
Datum der Freischaltung:27.12.2011
Jahrgang:6
Ausgabe / Heft:10: e26971
Seitenzahl:7
Erste Seite:1
Letzte Seite:7
HeBIS-PPN:287114961
Institute:Medizin / Medizin
Fachübergreifende Einrichtungen / Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit
DDC-Klassifikation:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Lizenz (Deutsch):License LogoCreative Commons - Namensnennung 3.0